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Abstract
Background: Multiple physiologic impairments are responsible for chronic wounds. A cell line grown
which retains its phenotype from patient wounds would provide means of testing new therapies. Clinical
information on patients from whom cells were grown can provide insights into mechanisms of specific
disease such as diabetes or biological processes such as aging.
The objective of this study was 1) To culture human cells derived from patients with chronic wounds and
to test the effects of putative therapies, Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) on
these cells. 2) To describe a methodology to create fibroblast cell lines from patients with chronic wounds.
Methods: Patient biopsies were obtained from 3 distinct locations on venous ulcers. Fibroblasts derived
from different wound locations were tested for their migration capacities without stimulators and in
response to GM-CSF. Another portion of the patient biopsy was used to develop primary fibroblast
cultures after rigorous passage and antimicrobial testing.
Results: Fibroblasts from the non-healing edge had almost no migration capacity, wound base fibroblasts
were intermediate, and fibroblasts derived from the healing edge had a capacity to migrate similar to
healthy, normal, primary dermal fibroblasts. Non-healing edge fibroblasts did not respond to GM-CSF. Six
fibroblast cell lines are currently available at the National Institute on Aging (NIA) Cell Repository.
Conclusion: We conclude that primary cells from chronic ulcers can be established in culture and that
they maintain their in vivo phenotype. These cells can be utilized for evaluating the effects of wound healing
stimulators in vitro.
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Introduction
Chronic wounds are defined not by their duration in time,
but by their multiple physiologic impairments to healing
[1-3]. Etiologic factors of chronic wounds such as neurop-
athy in persons with diabetes [4], venous reflux [5], or
compression of skin [6] are defined by more than 100
molecular and cellular impairments, such as inadequate
angiogenesis [7], impaired innervation [8], impaired cel-
lular migration [9] and abnormal keratinocyte activation
and differentiation[10]. A more accurate term than
"chronic wound" would be "physiologically impaired
wound".
Pressure ulcers and foot ulcers in persons with diabetes are
serious problems that can result in amputation, sepsis,
and even death without adequate intervention. Persons
with type 1 and type 2 diabetes have a 9.1% risk of devel-
oping a foot ulcer in their lifetime, [11] and the presence
of an ulcer increases their risk of lower extremity amputa-
tion almost 6-fold[12]. The 5-year survival rate for
patients with diabetes after major amputation is approxi-
mately 31%[13]. Venous stasis ulcers and their infectious
complications have not been well quantified but in our
experience result in numerous admissions across multiple
medical services. Debridement has become the standard-
of-care in patients with diabetes and a foot ulcer, pressure
ulcers and venous ulcers, to remove necrotic and infected
tissue and stimulate healing. In this study, we used debri-
ded tissue from venous ulcers as the basis to investigate
the cellular basis of impaired healing.
Various growth factors play a role in coordinating cellular
processes involved in wound healing. Platelet Derived
Growth Factor-BB (PDGF-BB) accelerates healing in part
by stimulating epithelialization and granulation tissue
formation [14]. Chronic wounds also demonstrate
decreased angiogenesis at the local level [15]. Angiogenic
growth factors such as Vascular Endothelial Growth Fac-
tors (VEGF) [16] (VEGF-c in mice); (VEGF-165), [17]
Granulocyte Macrophage Colony Stimulating Factor
(GM-CSF), [18] and Epidermal Growth Factor (EGF) [19]
are known to stimulate wound healing. In order to under-
stand how else GM-CSF might be involved in epitheliali-
zation and their non-angiogenic mechanisms of action,
we studied their effect on fibroblast migration.
Establishing cultures of fibroblasts from chronic wounds
for in vitro testing, although challenging, has been success-
ful for venous, pressure and diabetic foot ulcers. The first
studies of venous ulcers showed different morphology as
well as impaired fibroblast proliferation as shown by
punch biopsies from the wound edge as compared with
normal dermis [20]. Subsequent studies showed wound
fibroblasts grew significantly slower than control fibrob-
lasts taken from the same patient and the level of cellular
fibronectin was consistently higher in all wound-fibrob-
lasts[21]. Fibroblasts cultured from venous ulcers have
reduced collagen production response when stimulated
with TGF-β [22] and reduced proliferative response with
PDFG-BB [23] as compared with controls. Fibroblasts
have been isolated from venous stasis ulcers for in vitro
assay to evaluate cell cycle protein expression (p21) and
modulation by basic fibroblast growth factor (bFGF) [24].
Pressure ulcers have not been as widely studied but cells
grown from the wound bed exhibited slower proliferation
as compared to control skin[25].
Cultured fibroblasts from wounds in patients with diabe-
tes have been evaluated for mitogenic response with a
variety of growth factors [23,26] and show a lower rate of
proliferation when compared with normal skin. [27,28]
Beginning with morphological studies, previous investi-
gators have successfully performed a variety of assays on
cultured cells from venous ulcers[21,23]. Other investiga-
tors have evaluated various combinations of growth fac-
tors to see which stimulate mitogenic response and found
that combinations of PDGF-AB-IGFI, bFGF-PDGF-AB and
EGF-PDGF-AB elicited the highest response [26]. Taken
together, these studies support the notion that cells from
chronic wounds can be cultured and biologically evalu-
ated.
To date, novel therapeutic modalities are being tested in
animal models, such as ob/ob, db/db, NOD (non-obese
diabetic) mice and pigs. However, the specific pathogene-
sis that occurs in the chronic ulcer has not been success-
fully re-created in any of these models. Therefore, we
focused on establishing primary cell cultures originating
from actual patients and establishing cellular tests that
can help evaluate potential therapy on target wound cells.
In this report, we demonstrate that cells grown from
patients' wounds exhibit specific biological properties
that depend on their origin within the wound. Moreover,
these cells appear to maintain a distinct phenotype in cul-
ture, suggesting that they can be used as a tool to test
potential therapeutic agents.
Methods
Obtaining specimens of venous ulcers
After Institutional Review Board approval was obtained at
all institutions, human tissues from debrided venous
ulcers were used in the study. Debrided tissues from 4
patients (mean age of 53.5 ± 18.8 years (AVG ± SD) at the
time of specimen collection) were obtained using stand-
ard sterile surgical techniques.
The area of the wound was prepared with Betadine (Pur-
due, Stamford, CT). Three specific areas of the wound
were biopsied. A sterile #10 blade when was used to
biopsy the wound base, Location A. Then Location B was
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identified at the boundary of the wound bed and the rim
of necrotic or infected tissue to be removed. This area is
often identified by a callus. After biopsy of Location B, a
sharp excision was performed using to remove all the
entire circumferential ring of necrotic, nonviable scar or
infected tissue. Finally, a fresh blade was used to biopsy
several millimeters of adjacent non-wounded tissue,
(Location C, also known as the healing edge of the
wound) (see Figure 1). Cells from location B are those sur-
gically removed and cells from location C are the cells left
behind after surgery. One piece of the debrided tissue was
sent for routine pathology and other sections were imme-
diately processed for cell culture. Another portion of these
tissues were sent directly to the Aging Cell Repository at
Coriell Institute for Medical Research (Camden, NJ). Cells
derived from all four patients were subjected to tests
described below.
Cell migration assays
By using techniques previously described by us [9] and
others [29] we grew fibroblasts from the wound base
(location A), the non-healing edge (location B) and the
healing edge (location C) and compared their migration
capacities with normal primary dermal fibroblasts
(obtained from mammoplasty). Cells were grown in
(DMEM) (Bio Whittaker) containing 10% calf bovine
serum and 2% antibiotic – antimycotic (Gibco). Twenty-
four hours prior to the experiments cells were switched to
basal media – Phenol Red Free (DMEM) media (Bio Whit-
taker) supplemented by 2% charcoal – pretreated, bovine
serum as previously described [30] 1% antibiotic-antimy-
cotic (Gibco) and 1% L-glutamine (Cambrex Bio Science).
Prior to the scratch, cells were treated with 8 μg/ml Mito-
mycin C (ICN Biomedicals, Emeryville, CA) for 1 hour (to
inhibit cell proliferation) and washed with basal media.
Scratches were performed as previously described. [31]
Cells were incubated in the presence or absence of 100 ng/
ml GM-CSF (R&D Systems) or 25 ng/ml of EGF (Gibco)
for 24 and 48 hours and re-photographed 24 hrs after the
scratch. Fifteen measurements were taken for each experi-
mental condition and expressed as a percent of distance
coverage by cells moving into the scratch wound area for
each time point after wounding.
Preparation for cell culturing
Additional tissue from was sent to Coriell in 14 cc of Dul-
becco's Modified Eagle Medium (DMEM), supplemented
with 10% fetal calf serum (FCS), 4× Penicillin/Streptomy-
cin, and Gentamicin in 15 cc sterile tubes. They were
shipped overnight to Coriell at ambient temperature.
Routine histology was performed on a portion of all biop-
sies.
As part of the National Institutes on Aging (NIA) Cell
Repository at the Coriell Medical Institute for Medical
Research (Camden, NJ) fibroblast cultures were estab-
lished from the debrided tissue samples from patients
with chronic wounds. Fifteen biopsies were sent to Coriell
along with de-identified patients' medical history, history
of diabetes, age, sex, ethnicity, status of lower extremity
ischemia, and location of the biopsy.
Fibroblasts derived from patients
Fibroblast cultures were developed according to the stand-
ard procedure of the NIA Aging Cell Repository. Once
received, the biopsies were examined and, if large enough,
a portion was reserved as a Specimen Quality Control
sample for future use. The biopsies were finely minced
with two scalpels and placed in a T25 flask in a small vol-
ume of medium. For the establishment of the culture,
DMEM supplemented with 15% fetal calf serum, penicil-
lin (100 U/ml), Streptomycin (100 μg/ml) and Gen-
tamicin (50 μg/ml) was used. The flask was inverted and
4 ml additional medium was added. This facilitated the
rapid attachment of the cells from the biopsy to the flask.
After at least 4 hours (up to overnight), the flask was
returned to the upright position and the cells were cul-
tured for 5–7 days until they were 80% confluent. Cul-
tures were fed every 2–3 days. The fibroblasts were then
subcultured by a rinse with Puck's saline with EDTA fol-
lowed by incubation with Puck's/EDTA/Trypsin. An equal
volume of growth medium with serum was added, cells
were spun down, resuspended and plated in growth
medium without antibiotics.
After an expansion in antibiotic free media, cultures were
frozen in liquid N2. To test for viability and sterility, a vial
was recovered from the freezer, passaged five times and
tested for mycoplasmal, bacterial and fungal contami-
nants.
Sterility testing
Each culture was tested for mycoplasma using four tests,
PCR detection [32], staining using Hoechst dye, culturing
for Mycoplasma in broth [33], and culturing for Myco-
plasma on plates [33] Bacterial contaminants were
detected using the Gram Stain. No determination of the
species of bacteria was made.
Genotyping with microsatellites assures cell line identity 
and culture purity
To insure the identity of each sample, all freeze recoveries
and expansions of a cell line are genotyped, as well as
tested for species (human or non-human, based on the
presence of a specific Long Interspersed Nuclear Element
(LINE)) and gender.
The development of genotyping methods provides the
Coriell Cell Repositories (CCR) with the means to identify
Journal of Translational Medicine 2008, 6:75 http://www.translational-medicine.com/content/6/1/75
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Fibroblast deriving from different location of the wound exhibit different morphologyigure 1
Fibroblast deriving from different location of the wound exhibit different morphology. The picture of the wound is 
shown in the center. Circles indicate origin of specific locations from which biopsies were taken. Fibroblasts deriving from each 
location are shown. Cells from location B exhibit different phenotype (larger in size; clumped) whereas cells from Locations C 
and A exhibit phenotype similar to normal healthy fibroblasts.
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and track cell lines through all of the operations necessary
to establish the cultures.
CCR has established an extensive program of genotyping
based on microsatellite polymorphisms. Six highly poly-
morphic microsatellites have a combined matching prob-
ability of one in 33,000,000 for unrelated individuals. The
characteristics of each marker are provided in Table 1.
The alleles of all cell lines were determined by sizing on
the Applied Biosystems 3730, downloaded to the Reposi-
tory database, and compared to those already recorded to
assure correct identity. Gender determination was made
using the amelogenin marker. Additional genotyping
using Applied Biosystems AmpF/STR Identifier system
using 15 microsatellite markers (including the 13 Codis
markers) is used if required.
Results
Fibroblasts derived from biopsies of patients with venous 
ulcers exhibit pathogenic phenotype specific for the 
wound location
We found that fibroblasts chronic ulcers exhibit specific
morphological changes consistent with those previously
published[28]. The fibroblasts were larger in size and
breadth and clumped together, whereas in the control,
normal primary dermal fibroblasts were spindle-shaped
(Figure 1).
We found that fibroblasts from four venous ulcers origi-
nating from different locations in the wound migrate
more slowly than control cells (Figure 2). Furthermore,
we found that fibroblasts from various locations migrate
differentially. Cells from healing edge (location C)
migrate faster than either wound base or non-healing
edge fibroblasts. Cells from the wound-base (location A)
migrate faster than non-healing edge cells (location B).
Thus, cells from distinct locations within the wound have
distinct migration capacities reflecting their specific phe-
notypes.
Human recombinant GM-CSF accelerates migration of 
specific fibroblasts in the wound
To determine if GM-CSF stimulate migration of these
fibroblasts we used in vitro scratch-wound assays. Cells
derived from distinct wound locations were incubated in
the presence and absence of human recombinant GM-
CSF. Their response to wound healing stimuli was loca-
tion specific. We found that GM-CSF was the most effec-
tive in stimulating migration of fibroblasts deriving from
Location C, followed by those from Location A. Fibrob-
lasts from the non-healing edge (Location B) were not
responsive (Figures 3A, B and 3C, D). EGF was used as a
negative control, a growth factor to which fibroblasts do
not respond in this assay [note they do respond in many
other ways]. EGF did not have an effect on any of the cul-
tures (data not shown).
Human fibroblast cell line from chronic wounds
To establish whether the primary fibroblasts derived from
chronic wound biopsies maintained their functional and
structural features we grew fibroblasts from three loca-
tions in and around a chronic wound. Thirteen cultures
were frozen; one sample was contaminated before freez-
ing and one did not grow. Of these 13, 11 cultures were
shown to be viable and uncontaminated. To assure viabil-
ity and sterility, a vial was recovered from the freezer and
passaged 5 times and then tested for mycoplasmal, bacte-
rial and fungal contaminants. Six cultures are currently
available to the research community through the NIA Cell
Repository, http://ccr.coriell.org/Sections/Search/
Search.aspx?PgId=165&q=wound%20healing%20disord
er)
Discussion
Human fibroblast cell lines derived from patients with
chronic wounds were developed and future use along
with clinical data may provide information on specific
aspects of disease mechanisms involving particular pri-
mary cells derived from a wound. We utilized these cell
cultures to assay putative therapies for wound healing, i.e.,
gene therapies, utilizing GM-CSF as an example. We
found that cells grown from specific wound locations
have distinct phenotypes and diverse capacities to
respond to wound healing stimuli, such as GM-CSF.
Table 1: Characteristics of microsatellite markers.
Microsatellite Marker Range of Allele Sizes (bp) Heterozygosity pM (matching probability)
THO-1 154–178 0.77 0.086; 1 out of 12
D5S592 166–206 0.83 0.051; 1 out of 20
D10S526 182–266 0.84 0.017; 1 out of 59
vWA31 127–167 0.81 0.062; 1 out of 16
D22S417 172–213 0.85 0.039; 1 out of 25
FES/FPS 206–234 0.67 0.165; 1 out of 6
Also available online at http://ccr.coriell.org/Sections/Support/Global/QCgenotype.aspx?PgId=412
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Fibroblasts from the healing edges were found to be most
responsive, cells from the wound base had moderate
response, and cells from the non-healing edge showed
minimal response. As a result of this study, 6 fibroblast
cell lines, along with clinical data from patients with non-
healing wounds are available to researchers performing
similar assays via the NIA Aging Cell Repository at Coriell.
[34]
The reduced response of non-healing edge cells is not sur-
prising, as the cells appear to retain their phenotype in
vitro. It is surprising, then, that GM-CSF stimulated migra-
tion of these cells. GM-CSF is known as one of the major
growth factors that stimulates multiple cell types during
wound healing. Studies have shown that by acting on
keratinocytes GM-CSF promotes epithelialization and
wound closure. In addition, GM-CSF may stimulate pro-
duction of Fibronectin, Tenascin, Collagen I and alpha-
smooth muscle actin [35-37]. In vitro studies have demon-
strated that GM-CSF increases migration and proliferation
of endothelial cells suggesting a role in angiogenesis[38].
GM-CSF is chemotactic for macrophages to the wound
site, but such effect on fibroblasts is novel. This new find-
ing sheds light on additional mechanisms of these growth
factors in wound healing and suggests that GM-CSF has
multiple functions in wound healing in addition to
already established effects on angiogenesis.
Determination of the cellular response to growth factors
based on their location in the wound can guide surgeons
as to where to debride. Necrotic tissue impedes normal
healing. Sharp debridement with a scalpel is both the
most effective and readily available treatment to remove
necrotic tissue and in the process removes cells that can-
not respond as well to growth factors, i.e., cells from the
non-healing edge of the wound [3]. Debridement should
proceed until only the cells cultured from the post-debri-
dement edge – those that have the ability to respond to
growth factors or cellular therapy – remain. Obviously,
growing primary cells from each debrided non-healing
wound to guide debridement in operating room may not
be practical. However, once these studies are completed
and based on cellular responses one determines the loca-
tion of responsive cells within non-healing wound, such
knowledge would lead to determination of morphologi-
cal parameters that can be used in operating room. These
Cells from different wound locations exhibit distinct migration capacityFigure 2
Cells from different wound locations exhibit distinct migration capacity. Wound scratch assay is shown. Cells from 
Location C migrated equally to the healthy control whereas cells from Location B have the slowest rate.
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Human Recombinant GM-CSF Accelerate Migration of Fibroblasts deriving from Location CFigure 3
Human Recombinant GM-CSF Accelerate Migration of Fibroblasts deriving from Location C. Full lines indicate 
initial wound area; dotted lines demarcate migrating front of cells. GM – CSF treatment of fibroblasts deriving from location A 
(A) and location B (B). GM – CSF treatment of fibroblasts deriving from location C stimulated migration the most. (D) Surface 
area not covered by fibroblasts from scratch wounds are shown. GM-CSF markedly reduced wound area of fibroblasts from 
location C.
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cells generally correspond to hyperkeratotic and parakera-
totic tissue as determined by pathology results. In this
fashion, a "response margin" can be established in a
wound. Biopsies of tissue and their subsequent cell cul-
tures would define this response margin and indicate fur-
ther debridement. For the surgeon, findings presented
here are important as they illustrate the mechanism of
debridement at the cellular level and provide important
evidence for incorporating this procedure in treatment
protocols.
Determination of how actual human wound cells respond
to growth factors may provide important information as
to the potential efficacy of these potential therapies. Fur-
ther, it would establish data that could be used to expand
the scope of the current research and ultimately lead to a
clinical trial.
The best proxies for testing on the wound are cells from
the wound itself. It is evident from the literature that
many different assays, such as measurement of growth
factor production and response, expression of cell cycle
proteins, and cell morphology, hold a piece of the puzzle
as to why certain wounds do not heal. Part of the chal-
lenge is obtaining the best model to test potential thera-
pies. The fact that fibroblasts retain their distinct
phenotype in culture supports their use to test putative
therapies. Although the cultured fibroblasts retain their
phenotype in vitro we are currently investigating how
long the cell line fibroblasts retain their phenotype
through propagation.
Using the techniques described researchers can grow
fibroblasts from multiple locations in the wound, the
healing edge and non-healing edge to test putative thera-
pies. Although, this study highlights cells from venous
ulcers, researchers can use a similar methodology to cul-
ture cells from pressure ulcers and diabetic foot ulcers.
Also, recent study has shown that fibroblasts established
from the superficial dermis contains heterogeneous pop-
ulation of cells that has distinct morphology and prolifer-
ation kinetics [39].
The National Institute on Aging Cell Repository at Coriell
is the first containing cells strains derived from chronic
wounds. By using the methodology as described here,
researchers can produce their own cell lines from chronic
wounds in a standard fashion. These cell lines can provide
clinically valuable information on cells derived from
chronic ulcers.
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